$1.055
+0.058 (+5.50%)收盤時
- 最高
- 1.063
- 開盤
- 1.020
- 成交量加權均價
- 1.03
- 成交量
- 181.80K
- 市值
- —
- 最低
- 0.980
- 成交金額
- 187.71K
- 企業價值/稅息折舊攤銷前利潤（TTM）
- -1.29
MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd., is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, the Company unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
AI 分析 of MindWalk Holdings Corp (HYFT)
賣出MindWalk Holdings Corp (HYFT) is not a good buy right now due to its current price of $1.10, a very low RSI of 23.615 indicating oversold conditions, and a significant year-to-date change of -45.54%. The company has also reported consistent net losses, with a net income of -3,930,000 CAD in Q3 2026, which raises concerns about its profitability and sustainability. The main risk is the high debt to equity ratio of 50.41%, which could impact its financial stability.
估值指標
事件時間軸
資訊
7.511-04NewsfilterMindWalk Partners with Teva to Revolutionize Antibody Discovery
- 5.010-22Newsfilter
MindWalk Announces CBO Departure, Maintains Commercial Focus
- 7.510-21Newsfilter
Rapid Growth in Antibody Drug Market Driven by AI Innovations
- 8.510-14Newsfilter
MindWalk Strengthens Development Leadership, Advances Preclinical Research
5.010-01PRnewswireMindWalk Appoints New Director to Enhance Governance
HYFT 常見問題 —— 由 Alphio AI 解答
MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd., is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, the Company unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed. It operates in the Healthcare sector.
MindWalk Holdings Corp (HYFT) is not a good buy right now due to its current price of $1.10, a very low RSI of 23.615 indicating oversold conditions, and a significant year-to-date change of -45.54%. The company has also reported consistent net losses, with a net income of -3,930,000 CAD in Q3 2026, which raises concerns about its profitability and sustainability. The main risk is the high debt to equity ratio of 50.41%, which could impact its financial stability.
社群
更多 ↗暫無貼文
註冊或登入後參與討論相關文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。